# An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

> **NCT00933205** · — · APPROVED_FOR_MARKETING · sponsor: **Boehringer Ingelheim**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Tipranavir

## Key facts

- **NCT ID:** NCT00933205
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** 2004-05
- **Primary completion:** 2008-06
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2016-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00933205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00933205, "An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00933205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*